PubRank

John W Barrett

Author PubWeight™ 53.22‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Poxviruses and immune evasion. Annu Rev Immunol 2001 4.80
2 A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection. Immunity 2005 3.43
3 Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol 2004 2.51
4 Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A 2006 1.96
5 Four-pool modeling of proton exchange processes in biological systems in the presence of MRI-paramagnetic chemical exchange saturation transfer (PARACEST) agents. Magn Reson Med 2008 1.85
6 Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J Virol 2003 1.69
7 Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res 2007 1.50
8 RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog 2008 1.49
9 Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak. J Virol 2004 1.27
10 Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol 2006 1.25
11 Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo. J Virol 2005 1.20
12 Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther 2007 1.16
13 Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res 2008 1.08
14 Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of Bax at the mitochondria. J Virol 2006 1.06
15 M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A. J Virol 2006 1.05
16 Complete genomic sequence and comparative analysis of the tumorigenic poxvirus Yaba monkey tumor virus. J Virol 2003 1.05
17 Detection of circulating tumor cells in advanced head and neck cancer using the CellSearch system. Head Neck 2011 1.02
18 A secreted high-affinity inhibitor of human TNF from Tanapox virus. Proc Natl Acad Sci U S A 2003 1.02
19 A Pilot Study Comparing HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas by Whole Exome Sequencing. ISRN Oncol 2012 0.97
20 High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg 2013 0.95
21 Does HPV type affect outcome in oropharyngeal cancer? J Otolaryngol Head Neck Surg 2013 0.94
22 Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. Virology 2010 0.93
23 Frequent mutations in TP53 and CDKN2A found by next-generation sequencing of head and neck cancer cell lines. Arch Otolaryngol Head Neck Surg 2012 0.93
24 Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death. J Virol 2006 0.89
25 Induction of alpha/beta interferon by myxoma virus is selectively abrogated when primary mouse embryo fibroblasts become immortalized. J Virol 2009 0.88
26 Comparative genetic analysis of genomic DNA sequences of two human isolates of Tanapox virus. Virus Res 2007 0.86
27 Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2. Virology 2009 0.85
28 Tropism of Tanapox virus infection in primary human cells. Virology 2007 0.83
29 Synthesis and structure-activity relationships of indazole arylsulfonamides as allosteric CC-chemokine receptor 4 (CCR4) antagonists. J Med Chem 2013 0.82
30 Viral retasking of hBre1/RNF20 to recruit hPaf1 for transcriptional activation. PLoS Pathog 2013 0.81
31 Ki-67 expression predicts radiotherapy failure in early glottic cancer. J Otolaryngol Head Neck Surg 2012 0.81
32 Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Mol Ther 2010 0.81
33 Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbits. J Virol 2007 0.80
34 Variation in ligand binding specificities of a novel class of poxvirus-encoded tumor necrosis factor-binding protein. J Biol Chem 2006 0.80
35 Raccoonpox in a Canadian cat. Vet Dermatol 2006 0.80
36 Dendritic cell internalization of foam-structured fluorescent mesoporous silica nanoparticles. J Colloid Interface Sci 2010 0.80
37 Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer. BMC Pharmacol Toxicol 2014 0.79
38 Yaba monkey tumor virus encodes a functional inhibitor of interleukin-18. J Virol 2007 0.79
39 Vaccinia virus outperforms a panel of other poxviruses as a potent oncolytic agent for the control of head and neck squamous cell carcinoma cell lines. Intervirology 2013 0.78
40 The human papillomavirus E7 proteins associate with p190RhoGAP and alter its function. J Virol 2014 0.78
41 The tanapoxvirus 15L protein is a virus-encoded neuregulin that promotes viral replication in human endothelial cells. J Virol 2012 0.77
42 A case report and genetic characterization of a massive acinic cell carcinoma of the parotid with delayed distant metastases. Case Rep Oncol Med 2013 0.77
43 The extracellular domain of CD11d regulates its cell surface expression. J Leukoc Biol 2009 0.76
44 Development of a transoral robotic surgery program in Canada. J Otolaryngol Head Neck Surg 2013 0.75
45 Erratum: Numerical computations of the dynamics of fluidic membranes and vesicles [Phys. Rev. E 92, 052704 (2015)]. Phys Rev E 2016 0.75